Yahoo Finance’s Myles Udland and The Final Round panel break down and dig into the major tech earnings that came out after the bell on Thursday.
Yahoo Finance’s Myles Udland and The Final Round panel break down and dig into the major tech earnings that came out after the bell on Thursday.
Kai Havertz and Thiago Silva have both been included in Chelsea’s squad for the Champions League tie with Rennes tonight. Christian Pulisic is still recovering from a hamstring strain – but could be ready for the weekend’s top of the table showdown with Tottenham. Havertz has been out since testing positive for coronavirus before the international break.
Dublin, Nov. 24, 2020 (GLOBE NEWSWIRE) -- The "Nasal delivery devices Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Drug Type; Delivery Technologies; End User, and Geography" report has been added to ResearchAndMarkets.com's offering. The market is expected to reach US$ 95,676.62 million by2027 from US$ 58,502.18 million in 2019. The market is estimated to grow with a CAGR of 6.4% from 2020 to 2027. Based on delivery technologies, the market is segmented in to spray, nebulizers, inhalers, and others. In 2019, the inhalers segment held the largest share of the market and is expected to grow at the fastest CAGR during the forecast period. An inhaler (also known as a pump, puffer, or allergy spray) is a nasal delivery device used for delivering medicines into the lungs via person's breathing mechanism. This device helps deliver medical treatment to the targeted region of the body, thereby reducing the side effects of oral medications. There are a wide variety of inhalers that are used to treat numerous medical conditions, such as asthma and chronic obstructive pulmonary disease (COPD). Some of the common types of inhalers include meter-dosed inhalers, dry powder inhalers, soft mist inhalers, and others. There are certain types of inhalers containing drugs in it for the treatment of asthma and COPD such as , reliever inhalers: contain bronchodilator medicines, preventer inhalers: contain a steroid medicine. GlaxoSmithKline plc.; AstraZeneca; Pfizer Inc.; BD; Sanofi; Merck & Co.Inc.; Cadila Pharmaceuticals Ltd.; Novartis AG; Dr. Reddy's Laboratories; and Neurelis, Inc. are among the leading companies operating in the nasal delivery devices market. Key Topics Covered: 1. Introduction1.1 Scope of the Study1.2 Report Guidance1.3 Market Segmentation2. Nasal Delivery Devices Market - Key Takeaways3. Research Methodology4. Global Nasal Delivery Devices Market - Market Landscape4.1 Overview4.2 PEST Analysis4.3 Expert Opinion5. Nasal Delivery Devices Market - Key Market Dynamics5.1 Market Drivers5.1.1 Growing Prevalence of Respiratory and CNS Diseases5.1.2 Increasing Preference and Awareness Among Patients5.2 Market Restraints5.2.1 Challenges Associated with Nasal Administration of Drugs5.3 Market Opportunities5.3.1 Rising Adoption of Self-Administration Practices5.4 Future Trends5.4.1 Consolidation of Nasal Delivery Device Industry5.5 Impact Analysis6. Nasal Delivery Devices Market - Global Analysis6.1 Global Nasal Delivery Devices Market Revenue Forecast And Analysis6.2 Global Nasal Delivery Devices Market, By Geography - Forecast And Analysis6.3 Market Positioning of Key Players7. Nasal Delivery Devices Market Analysis - By Drug Type7.1 Overview7.2 Nasal Delivery Devices Market Revenue Share, by Drug Type (2019 and 2027)7.3 Anesthetics7.3.1 Overview7.3.2 Anesthetics: Nasal Delivery Devices - Revenue and Forecast to 2027 (US$ Million)7.4 Antibiotics7.5 Pain Relief Drugs7.6 Calcium Supplements7.7 Vasoconstrictors7.8 Antihistamines8. Nasal Delivery Devices Market Analysis - By Delivery Technologies8.1 Overview8.2 Nasal Delivery Devices Market Revenue Share, by Delivery Technologies (2019 and 2027)8.3 Spray8.3.1 Overview8.3.2 Spray: Nasal Delivery Devices - Revenue and Forecast to 2027 (US$ Million)8.4 Nebulizers8.5 Inhalers9. Nasal Delivery Devices Market Analysis - By End -User9.1 Overview9.2 Nasal Delivery Devices Market Revenue Share, by End -User (2019 and 2027)9.3 Home Care Setting9.3.1 Overview9.3.2 Home Care Setting: Nasal Delivery Devices - Revenue and Forecast to 2027 (US$ Million)9.4 Hospitals9.5 Clinics10. Nasal Delivery Devices Market - Geographic Analysis11. Impact of COVID-19 Pandemic on Global Nasal Delivery Devices Market12. Nasal Delivery Devices Market- Industry Landscape12.1 Overview12.2 Growth Strategies Done by the Companies in the Market, (%)12.3 Organic Developments12.4 Inorganic Developments13. Company Profiles13.1 Key Facts13.2 Business Description13.3 Products and Services13.4 Financial Overview13.5 SWOT Analysis13.6 Key Developments GlaxoSmithKline plc.AstraZenecaPfizer Inc.BDSanofiMerck & Co., Inc.Cadila Pharmaceuticals Ltd.Novartis AGDr. Reddy's LaboratoriesNeurelis, Inc. For more information about this report visit https://www.researchandmarkets.com/r/v0xqp0 Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Annette Guzman-Torres was feeling discouraged and frustrated, her anxiety fueled by the uncertainty of a bleak job market during the coronavirus pandemic. The 44-year-old married mother of two boys is close to finishing the capstone project for her doctorate from Capella University. “I was like, I have no job, nowhere to go, nothing to do,” said the resident of Bloomfield, New Jersey.
Boris Johnson is thrashing out plans with the devolved leaders for families to reunite over Christmas amid hopes that restrictions under the new Covid tier system will be over by Easter. Talks between the Government and Scotland, Wales and Northern Ireland are continuing in a bid to find a common approach to household mixing over the festive period. Mr Johnson confirmed on Monday that England will return to a regional tier system from December 2, but was unable to spell out any further details for Christmas.
Directors had set up rescue refinancing but investors demand better deal
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR IN ANY JURISDICTION IN WHICH THE DISTRIBUTION, PUBLICATION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY, NOR SHALL THERE BE ANY SALE OF THE SECURITIES REFERRED TO HEREIN, IN OR INTO ANY JURISDICTION WHERE SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH JURISDICTION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT. Tryg A/S, has received the following information from Danske Bank A/S and Morgan Stanley & Co. International plc: Further to the announcement on 23 November 2020, Danske Bank A/S (“Danske Bank”) and Morgan Stanley & Co. International plc (“Morgan Stanley”) (together “the Managers”) announce that TryghedsGruppen smba (“TryghedsGruppen”) has agreed to sell 21,149,745 existing shares in Tryg A/S (“Tryg”), equivalent to 7% of the existing shares in Tryg to institutional investors at a price of DKK 170 per share, pursuant to an accelerated bookbuild offering (the “Transaction”). Danske Bank and Morgan Stanley acted as Joint Global Coordinators and Joint Bookrunners in the Transaction. Following settlement of the Transaction (which is subject to customary closing conditions and expected to be on 26 November 2020), TryghedsGruppen will hold 53% of the existing shares in Tryg. In connection with the Transaction, TryghedsGruppen has undertaken to the Managers that, subject to certain exceptions, for a specific period of time (the “Lock-Up Period”) it will not dispose of any Tryg shares which are not sold in the Transaction without the prior written consent of the Managers. The Lock-Up Period means the shorter of (i) 180 calendar days from the first day of trading of any new Tryg shares in the ISIN code of its existing shares, that may be issued in connection with the Rights Issue; and (ii) 365 calendar days after the date of 23 November 2020. Tryg will not receive any proceeds from the Transaction. Contact informationGianandrea Roberti, Investor Relations Officer +45 20 18 82 67 email@example.comPeter Brondt, Investor Relations Manager +45 22 75 89 04 firstname.lastname@example.orgTanja Frederiksen, Head of Communications +45 51 95 77 78 email@example.com Important InformationTHIS ANNOUNCEMENT DOES NOT CONSTITUTE, OR FORM PART OF, AN OFFER TO SELL, OR A SOLICITATION OF AN OFFER TO PURCHASE ANY SECURITY IN THE UNITED STATES. THE SECURITIES REFERRED TO HEREIN HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES EXCEPT TO “QUALIFIED INSTITUTIONAL BUYERS” AS DEFINED IN RULE 144A UNDER THE SECURITIES ACT PURSUANT TO AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. ALL OFFERS AND SALES OF SECURITIES OUTSIDE OF THE UNITED STATES WILL BE MADE IN RELIANCE ON, AND IN COMPLIANCE WITH, REGULATION S UNDER THE SECURITIES ACT. THERE IS NO INTENTION TO MAKE A PUBLIC OFFERING OF THE SECURITIES IN THE UNITED STATES. THE SECURITIES MAY NOT AND WILL NOT BE OFFERED OR SOLD IN CANADA, JAPAN AND AUSTRALIA. WITH RESPECT TO THE MEMBER STATES OF THE EUROPEAN ECONOMIC AREA SUBJECT TO REGULATION 2017/1129/EU (TOGETHER WITH ANY APPLICABLE IMPLEMENTING MEASURES, THE “PROSPECTUS REGULATION”) (EACH A “RELEVANT MEMBER STATE”), NO ACTION HAS BEEN UNDERTAKEN OR WILL BE UNDERTAKEN TO MAKE AN OFFER TO THE PUBLIC OF THE SECURITIES REFERRED TO HEREIN REQUIRING THE PUBLICATION OF A PROSPECTUS IN ANY RELEVANT MEMBER STATE. AS A RESULT, THESE SECURITIES MAY ONLY BE OFFERED OR SOLD IN ANY RELEVANT MEMBER STATE PURSUANT TO AN EXEMPTION UNDER THE PROSPECTUS REGULATION. THIS ANNOUNCEMENT IS ONLY ADDRESSED TO, AND DIRECTED AT, PERSONS IN RELEVANT MEMBER STATES OF THE EUROPEAN ECONOMIC AREA WHO ARE “QUALIFIED INVESTORS” WITHIN THE MEANING OF ARTICLE 2(e) OF THE PROSPECTUS REGULATION (“QUALIFIED INVESTORS”). IN THE UNITED KINGDOM, THIS ANNOUNCEMENT IS DIRECTED ONLY AT, QUALIFIED INVESTORS (I) WHO ARE “INVESTMENT PROFESSIONALS” FALLING WITHIN ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (THE “ORDER”), OR (II) PERSONS FALLING WITHIN ARTICLE 49(2)(A)-(D) (“HIGH NET WORTH COMPANIES, UNINCORPORATED ASSOCIATIONS ETC”) OF THE ORDER ALL SUCH PERSONS TOGETHER BEING REFERRED TO AS (“RELEVANT PERSONS”). UNDER NO CIRCUMSTANCES SHOULD PERSONS WHO ARE NOT RELEVANT PERSONS RELY OR ACT UPON THE CONTENTS OF THIS ANNOUNCEMENT. ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IN THE UNITED KINGDOM IS AVAILABLE ONLY TO, AND WILL BE ENGAGED ONLY WITH, RELEVANT PERSONS. IN DENMARK, THIS PRESS RELEASE IS DIRECTED ONLY AT PERSONS WHO ARE QUALIFIED INVESTORS. DANSKE BANK AND MORGAN STANLEY ARE ACTING FOR TRYGHEDSGRUPPEN AND FOR NO ONE ELSE IN CONNECTION WITH THE TRANSACTION AND WILL NOT BE RESPONSIBLE TO ANYONE OTHER THAN TRYGHEDSGRUPPEN FOR PROVIDING THE PROTECTIONS AFFORDED TO CUSTOMERS OF DANSKE BANK AND MORGAN STANLEY OR FOR AFFORDING ADVICE IN RELATION TO THE TRANSACTION, THE CONTENTS OF THIS ANNOUNCEMENT OR ANY TRANSACTION, ARRANGEMENT OR OTHER MATTER REFERRED TO IN THIS ANNOUNCEMENT. EITHER OF THE MANAGERS MAY PARTICIPATE IN THE TRANSACTION ON A PROPRIETARY BASIS. THIS ANNOUNCEMENT HAS BEEN ISSUED BY DANSKE BANK AND MORGAN STANLEY ON BEHALF OF TRYGHEDSGRUPPEN AND IS THE SOLE RESPONSIBILITY OF TRYGHEDSGRUPPEN. APART FROM THE RESPONSIBILITIES AND LIABILITIES, IF ANY, THAT MAY BE IMPOSED ON MORGAN STANLEY BY THE FINANCIAL SERVICES AND MARKETS ACT 2000, DANSKE BANK AND MORGAN STANLEY DO NOT ACCEPT ANY RESPONSIBILITY WHATSOEVER AND MAKE NO REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, FOR THE CONTENTS OF THIS ANNOUNCEMENT, INCLUDING ITS ACCURACY, COMPLETENESS OR VERIFICATION OR FOR ANY OTHER STATEMENT MADE OR PURPORTED TO BE MADE BY TRYGHEDSGRUPPEN, OR ON TRYGHEDSGRUPPEN’S BEHALF, OR BY DANSKE BANK AND MORGAN STANLEY OR ON DANSKE BANK AND MORGAN STANLEY’S BEHALF, IN CONNECTION WITH TRYGHEDSGRUPPEN OR THE TRANSACTION, AND NOTHING IN THIS ANNOUNCEMENT IS OR SHALL BE RELIED UPON AS A PROMISE OR REPRESENTATION IN THIS RESPECT, WHETHER AS TO THE PAST OR FUTURE. DANSKE BANK AND MORGAN STANLEY ACCORDINGLY DISCLAIM TO THE FULLEST EXTENT PERMITTED BY LAW ALL AND ANY RESPONSIBILITY AND LIABILITY, WHETHER ARISING IN TORT, CONTRACT OR OTHERWISE, WHICH THEY MIGHT OTHERWISE HAVE IN RESPECT OF THIS DOCUMENT AND ANY SUCH STATEMENT. Attachment 16_2020_Sale of 21,149,745 existing shares in Tryg
Black Friday iRobot Roomba deals for 2020, including Roomba s9, s9+, i7, 980 & more robovac deals
The government has announced a maximum of 4,000 fans will be allowed in low-risk areas.
I have a distinct memory of my dad telling me a certain boyfriend “wasn’t worth it”. I was 16. It had been my first love, and we’d just broken up. “You’re a beautiful girl, Laura,” my dad said to me, while driving. “You’re smart and you don’t have to put up with someone who makes you sad.” It’s simple advice but it stuck. I reminded myself of his words often in the following years, usually following a breakup. But when my longest relationship ended late last year, my dad was no longer able to give me the same speech. The breakup unfortunately coincided with the gradual loss of my father to dementia. It was a horrible experience: I found out that my boyfriend of five years had cheated on me while I was visiting my parents in New Zealand. My dad’s health was rapidly deteriorating and my mum feared it would be the last time I saw him, so I attempted to hide my heartbreak. I flew back to New York, where my partner and I lived together, to find myself single for the first time since college. After the official split, one of the first places my mind went to was that conversation I had as a teenager with my dad. While my ex-boyfriend packed his bags and moved out, the memory of those words was my only source of comfort. Very quickly, I entered the dating world — for all the wrong reasons. My ex had started seeing someone in Paris, parading her around places we had visited only a few months prior, on an anniversary trip no less. My natural reaction was to enter the unspoken game of who cares less. I developed a routine: Go out on a date that I wasn’t ready for, come home alone to a house that felt empty, check my ex’s Instagram stories, then message or call my mother to ask how my father was doing in the dementia home he had just moved into back in New Zealand. During this time, it’s no surprise that the connections I made weren’t healthy. I downplayed the heartbreak I felt over my ex and completely avoided talking about the nightmare happening at home. I accepted treatment that I otherwise wouldn’t have, grew tired of people quickly, and ended things with anyone who was remotely “too nice” to me. “You’re just too happy, and I’m really not,” is an excuse I’m ashamed to admit I used. I was grieving the slow loss of my father and the abrupt loss of my relationship. My ex-boyfriend had become like family to me, and I was living far away from our home in New Zealand. In that state, my search for a new partner was getting confused with a search for a sense of security. But I quickly learned that forcing intimacy with someone I wasn’t entirely into left me feeling worse than I did alone. I’d often leave dates wishing I liked the person, giving them a second or third date in the hopes that I eventually would, then starting over with someone new when I realised I was ultimately uninterested. By luck, I ended up on a date with someone who soon became my best friend. Though we were both unavailable for a romantic relationship, we went to events together, had movie nights, and scheduled dinners every week, in a dynamic that felt comforting and loving. He was also a writer, and we’d read each other’s work and have lengthy discussions about our concerns around romance. Slowly, I began to open up to him about my father. While he moved away during the pandemic, in hindsight, I can see how our interactions gave me insight into how a less traditional partnership could take shape, creating something that’s sustainable, and enjoyable, for the more long-term future. We’re still building on our relationship every day. My father passed away a few months ago, in August. By then, I found myself in a place where dating was the lowest thing on my priority list — and instead of reaching out to a new partner, I was immediately surrounded by love and support from true friends. While I’d already decided to be more intentional with dating, my dad’s words to me as a teenager took on a new importance. They became a guiding force, encouraging me to cut ties with anyone who wasn’t adding value to my life and to unlearn the societal pressure that teaches us that our worth as humans comes from how desirable other people find us to be. For me, this looks like speaking to fewer people, saying no more often, and putting more energy into friendships and self-development. I put this into practice during my first dating experience since my father’s passing. During dinner, I noticed that I wasn’t feeling supported. My date spoke over me while I discussed my work and made subtle jokes about my interests, even though he had very few of his own. However good he seemed on paper and however faint the orange flags may have been, my father’s advice inspired me to opt out of seeing what the next date would bring. While this may seem like a small step, it felt empowering to choose to be single rather than pursuing the wrong relationship for the sake of being in one. Three months since my dad’s death, that ongoing work has led to me being the most happily single I’ve ever been. Without my dad to look out for me, I’ve found myself more eager to look out for myself. I’ve also made the decision to keep my family name if I ever decide to get married (something I’m very much on the fence about). While there have been moments where the loss has left me feeling the urge to make more connections, I’ve built a complete life outside of dating that I hope will only be complemented (not made) by anyone I choose romantically. I doubt my father had any idea that a car conversation we had about a teenage boyfriend would become my go-to principal through dating as an adult. But his advice rings true for all of us. Too often the pressure to feel desirable or not be alone, especially for female-identifying people, leads us into romantic situations that are just not “worth it.” Interrogating that idea has led me to a healthier outlook on being single. Guided by my father’s wisdom, deprioritising romance during this time has been more fulfilling than I ever expected. Which is why it’s also my plan moving forward. For my dad’s sake, I intend to advocate for myself as strongly as I know he would, if he were still alive. Like what you see? How about some more R29 goodness, right here?I Stopped Wearing A Hijab & Started DatingWhat It’s Like To Get Dumped During A Pandemic9 Women On Dating During The Pandemic
ANNOUNCEMENT NO. 101 - 24 NOVEMBER 2020 In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcement no. 90. Kind regards, Dampskibsselskabet NORDEN A/S Martin Badsted CFO For further information: Martin Badsted, CFO, tel.: +45 3315 0451 Attachments No. 101 Managers' transactions Transactions by persons discharging managerial responsibilities and persons
Lionel Messi might be a Manchester man after all.
Donald Trump has accepted that a formal transition can begin for Joe Biden to take office. Mr Biden was declared the “apparent winner” of the US election by a key federal agency, clearing the way for the start of the transition. President Trump, who had refused to concede the election, said he was directing his team to co-operate on the transition but vowed to keep up the fight.
Daniel Dubois and Joe Joyce finally lock horns in an eagerly-anticipated all-London British heavyweight fight this weekend. Only once has Dubois been taken beyond five rounds - in his points win over journeyman Kevin Johnson back in 2018. A decorated amateur who previously claimed Commonwealth and European gold in addition to Olympic silver - at Rio 2016 - and World Championship bronze, Joyce turned professional at the age of 31 and has since racked up 11 wins from as many bouts, with 10 KOs of his own.
Save on a selection of Dyson cordless vacuum deals at the Black Friday sale, featuring all the latest Cyclone V10 and V11 Animal offers
UK diplomat who saved Chinese woman given traditional bannerChongqing consul-general Stephen Ellison jumped into river to save university student
Travellers arriving in England will be able to end their quarantine period after five days from December 15, if they pay for a coronavirus test that comes back negative. The travel industry welcomed the policy, announced by Transport Secretary Grant Shapps, but described it as "long overdue". Under the new rules, passengers who arrive from a destination not on the Government's travel corridors list will still need to enter self-isolation.
Dublin, Nov. 24, 2020 (GLOBE NEWSWIRE) -- The "Gastrointestinal Drugs Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Drug Class; Route of Administration; Application; Distribution Channel, and Geography" report has been added to ResearchAndMarkets.com's offering. The market is expected to reach US$ 71,300.28 million in 2027 from US$ 49,043.38 million in 2019. The market is estimated to grow at a CAGR of 4.9% from 2020 to 2027. The report highlights trends prevailing in the market, and drivers and hindrances pertaining to the market growth. Based on drug class, the market is segmented in to acid neutralizers, antidiarrheal and laxatives, anti-inflammatory drugs, antiemetic and antinauseants, biologics, and others. In 2019, the acid neutralizers segment held the largest share of the market. The biologics segment is expected to grow at the fastest CAGR during the forecast period. The advent of biologics has had a significant impact on the management of inflammatory bowel disease (IBD). Treatment with biologics has led to an improved quality of life for patients living with Crohn's disease and ulcerative colitis, with fewer admissions to the hospital and less side effects from corticosteroids. These are the most recently developed treatments for IBD. Biologic therapies are indicated for people with moderately to severely active disease who have not responded well to conventional therapy. Four of these agents (adalimumab, certolizumab pegol, golimumab and infliximab) target an inflammatory protein called tumor necrosis factor (TNF). Natalizumab and vedolizumab work by blocking certain types of white blood cells from getting into inflamed tissues. Biologics are beneficial for patients with gastrointestinal disorders who are not responding to conventional treatment. For instance, infliximab, which is derived from monoclonal antibodies to tumor necrosis factor is another modifier of the immune system's actions. Infliximab is given as a series of infusions by vein. This drug can be given to treat moderate to severe Crohn's disease that has not responded to other drugs, to treat people with fistulas, and to maintain response when the disease is difficult to control. Vedolizumab and natalizumab are drugs for people who have moderate to severe Crohn's diseasethat have not responded to TNF inhibitors or other immunomodulating drugs. With the increasing number of biologics in pipeline, the segment is expected to grow at a rapid pace during the forecast period. For instance, Takeda Pharmaceutical Company Limited has five candidates in different phases for various GI indications. Sanofi; GlaxoSmithKline plc; Johnson and Johnson Services, Inc.; Bausch Health; AstraZeneca; Takeda Pharmaceutical Company Limited; AbbVie Inc.; Bayer AG; Celltrion Healthcare Co. , Ltd; and LEXICON PHARMACEUTICALS, INC. are among the leading companies operating in the gastrointestinal drugs market. Key Topics Covered: 1. Introduction1.1 Scope of the Study1.2 Report Guidance1.3 Market Segmentation2. Gastrointestinal Drugs Market - Key Takeaways3. Research Methodology4. Global Gastrointestinal Drugs- Market Landscape4.1 Overview4.2 PEST Analysis4.3 Expert Opinions5. Gastrointestinal Drugs Market- Key Market Dynamics5.1 Key Market Drivers5.1.1 Rise in Prevalence of Gastrointestinal (GI) Diseases5.1.2 Increase in Development of Biologics5.2 Market Restraints5.2.1 Low Awareness Associated with Gastrointestinal Disorders in Low-Income Economies5.3 Market Opportunities5.3.1 Increasing Investment in Research Activities and Growing Pipeline of GI Candidates5.4 Future Trends5.4.1 Emergence of Biosimilars5.5 Impact Analysis6. Gastrointestinal Drugs Market - Global Analysis6.1 Global Gastrointestinal Drugs Marker Revenue Forecast And Analysis6.2 Global Gastrointestinal Drugs Market, By Geography - Forecast And Analysis6.3 Market Positioning of Key Players7. Gastrointestinal Drugs Market Analysis - By Drug Class7.1 Overview7.2 Gastrointestinal Drugs Market Revenue Share, by Drug Class (2019 and 2027)7.3 Acid Neutralizers7.3.1 Overview7.3.2 Acid Neutralizers: Gastrointestinal Drugs Market - Revenue and Forecast to 2027 (US$ Million)7.4 Antidiarrheal and Laxatives7.5 Anti-Inflammatory Drugs7.6 Antiemetic and Antinauseants7.7 Biologics8. Gastrointestinal Drugs Market Analysis - By Route of Administration8.1 Overview8.2 Gastrointestinal Drugs Market Share, by Route of Administration, 2019 and 20278.3 Oral8.3.1 Overview8.3.2 Oral: Gastrointestinal Drugs Market - Revenue and Forecast to 2027 (US$ Million)8.4 Parenteral9. Gastrointestinal Drugs Market Analysis - By Application9.1 Overview9.2 Gastrointestinal Drugs Market Revenue Share, by Application (2019 and 2027)9.3 Inflammatory Ulcerative Colitis9.3.1 Overview9.3.2 Inflammatory Ulcerative Colitis: Gastrointestinal Drugs Market - Revenue and Forecast to 2027 (US$ Million)9.4 Crohn's Disease9.5 Irritable Bowel Syndrome9.6 Gastroenteritis9.7 Celiac Disease10. Gastrointestinal Drugs Market Analysis - By Distribution Channel10.1 Overview10.2 Gastrointestinal Drugs Market Share, by Distribution Channel, 2019 and 202710.3 Hospital Pharmacies10.3.1 Overview10.3.2 Hospital Pharmacies: Gastrointestinal Drugs Market - Revenue and Forecast to 2027 (US$ Million)10.4 Retail Pharmacies10.5 Online Pharmacies11. Gastrointestinal Drugs Market Analysis And Forecast To 2027 - Geographical Analysis12. Impact of COVID-19 Pandemic on Global Gastrointestinal Drugs Market13. Gastrointestinal Drugs Market-Industry Landscape13.1 Overview13.2 Growth Strategies Done by the Companies in the Market, (%)13.3 Organic Developments13.4 Inorganic Developments14. Company Profiles14.1 Key Facts14.2 Business Description14.3 Products and Services14.4 Financial Overview14.5 SWOT Analysis14.6 Key Developments SanofiGlaxoSmithKline plcJohnson and Johnson Services, Inc.Bausch HealthAstraZenecaTakeda Pharmaceutical Company LimitedAbbVie Inc.Bayer AGCelltrion Healthcare Co.,LtdLexicon Pharmaceuticals, Inc For more information about this report visit https://www.researchandmarkets.com/r/ru8ywm Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Follow the latest updates
Children in crisis: Councils an ‘invisible crisis’ played out during lockdown as social workers warn surge in domestic violence, alcohol abuse and anxiety has put caseloads at an all-time high
The Chancellor will outline where money will be spent and saved as the UK deals with the economic shock of the pandemic.